Economic evaluation: A comparison of methadone versus buprenorphine for opiate substitution treatment

Drug and Alcohol Dependence

Volumn 133, Issue 2, 2013, Pages 494-501

  Maas, Jim ^a   Barton, Garry ^a   Maskrey, Vivienne ^a   Pinto, Hayley ^b   Holland, Richard ^a  

^a UNIVERSITY OF EAST ANGLIA   (United Kingdom)

^b NORFOLK AND SUFFOLK NHS FOUNDATION TRUST   (United Kingdom)

Author keywords

Buprenorphine; Cost effectiveness; Methadone; Substitution; Treatment

Indexed keywords

BUPRENORPHINE; METHADONE;

ARTICLE; COMPARATIVE STUDY; CONTROLLED STUDY; COST; COST BENEFIT ANALYSIS; COST EFFECTIVENESS ANALYSIS; DISPENSING COST; DRUG CHOICE; DRUG COST; FEE; HUMAN; OPIATE SUBSTITUTION TREATMENT; PHARMACY SUPERVISION COST; PRESCRIPTION; PRIORITY JOURNAL; UNITED KINGDOM;

BUPRENORPHINE; COST EFFECTIVENESS; METHADONE; SUBSTITUTION; TREATMENT;

BUPRENORPHINE; COST-BENEFIT ANALYSIS; COSTS AND COST ANALYSIS; DRUG COSTS; HEALTH CARE COSTS; HEALTH PERSONNEL; HEROIN DEPENDENCE; HUMANS; METHADONE; NARCOTICS; OPIATE SUBSTITUTION TREATMENT; OPIOID-RELATED DISORDERS; PATIENT COMPLIANCE; PHARMACIES; SUBSTANCE ABUSE DETECTION; TREATMENT OUTCOME;

EID: 84887014967     PISSN: 03768716     EISSN: 18790046     Source Type: Journal    
DOI: 10.1016/j.drugalcdep.2013.07.018     Document Type: Article

References (22)

1. Barnett P.G. Comparison of costs and utilization among buprenorphine and methadone patients. Addiction 2009, 104:982-992.
2. Christo G., Spurrell S., Alcorn R. Validation of the Christo Inventory for Substance-misuse Services (CISS): a simple outcome evaluation tool. Drug Alcohol Depend 2000, 59:189-197.
3. Colombo G.L., Faillace G., Ferdico M. Analisi dei costi di Buprenorfina vs. Metadone nella terapia dei soggetti con dipendenza da oppiacei 2003, Farmeconomia e percorsi terapeutici, Torino (Turin) Italy.
4. Connock M., Juarez-Garcia A., Jowett S., Frew E., Liu Z., Taylor R., Fry-Smith A., Day E., Lintzeris N., Roberts T. Methadone and Buprenorphine for the Management of Opioid Dependence: A Systematic Review and Economic Evaluation 2007, Gray Publishing, Birmingham.
5. Curtis L.A. Unit Costs of Health and Social Care 2011 2011, Personal Social Services Research Unit, University of Kent, Kent.
6. Drummond M.F. Methods for the Economic Evaluation of Health Care Programmes 2005, Oxford University Press, Oxford.
7. European Monitoring Centre for Drugs and Drug Addiction The EMCDDA annual report 2010: the state of the drugs problem in Europe. Eurosurveillance 2010, 49-49.
8. Fowler J., Emerson J., Allen A., Dilley S., Gideonse N., Rieckmann T., Risser A., Caughey A. Buprenorphine vs. methadone for maintenance of opioid addiction during pregnancy: a cost-effectiveness analysis. Am J Obstet Gynecol 2013, 208:S65-S66.
9. Harris A.H., Gospodarevskaya E., Ritter A.J. A randomised trial of the cost effectiveness of buprenorphine as an alternative to methadone maintenance treatment for heroin dependence in a primary care setting. Pharmacoeconomics 2005, 23:77-91.
10. Jones E.S., Moore B.A., Sindelar J.L., O'Connor P.G., Schottenfeld R.S., Fiellin D.A. Cost analysis of clinic and office-based treatment of opioid dependence: results with methadone and buprenorphine in clinically stable patients. Drug Alcohol Depend 2009, 99:132-140.
11. Maremmani I., Gerra G. Buprenorphine-based regimens and methadone for the medical management of opioid dependence: selecting the appropriate drug for treatment. Am J Addict 2010, 19:557-568.
12. ®) in Spain. Health Econ Rev 2012, 2:3.
13. Mattick R.P., Kimber J., Breen C., Davoli M. Buprenorphine maintenance versus placebo or methadone maintenance for opioid dependence. Cochrane Database Syst Rev C 2008, CD002207.
14. Maynard A., Street A., Hunter R. Using 'payment by results' to fund the treatment of dependent drug users - proceed with care. Addiction 2011, 106:1725-1729.
15. National Health Service England and Wales Electronic Drug Tariff 2010, NHS Business Services Authority, N.P.S., London.
16. National Institute for Health and Clinical Excellence Methadone and Buprenorphine for the Management of Opiod Dependence 2010, NICE, London.
17. Pinto H., Maskrey V., Swift L., Rumball D., Wagle A., Holland R. The SUMMIT trial: a field comparison of buprenorphine versus methadone maintenance treatment. J Subst Abuse Treat 2010, 39:340-352.
18. Royse D., Drude K. Screening drug abuse clients with the brief symptom inventory. Intl J Addict 1984, 19:849-857.
19. Russell C., McKeganey N. A cost-effectiveness analysis of extending methadone and buprenorphine-naloxone maintenance treatment of opioid dependence from eight to sixteen months. Value Health 2013, 16:A61.
20. Shanahan M.D., Doran C.M., Digiusto E., Bell J., Lintzeris N., White J., Ali R., Saunders J.B., Mattick R.P., Gilmour S. A cost-effectiveness analysis of heroin detoxification methods in the Australian National Evaluation of Pharmacotherapies for Opioid Dependence (NEPOD). Addict Behav 2006, 31:371-387.
21. Singleton N., Farrell M., Meltzer H. Substance misuse among prisoners in England and Wales (Reprinted from Office for National Statistics, 1999). Int Rev Psychiatr 2003, 15:150-152.
22. Uddin M., Maskrey V., Holland R. A study to validate a self-reported version of the ONS drug dependence questionnaire. J Subst Use 2011, 16:273-281.